Uncategorized

Recent clinical studies have shown that CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy is effective and safe for patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Combining CAR-T therapy with transplantation has the potential to enhance treatment efficacy and reduce disease recurrence. Most existing studies have implemented CD7 CAR-T cells as a bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recently, Professor Chun Wang’s team at Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital successfully applied a new approach: post-allo-HSCT infusion of donor-derived CD7 CAR-T cells to treat a case of refractory T-ALL/LBL. This study, published in Frontiers in Immunology, offers new strategies for treating R/R T-ALL/LBL patients. We conducted an exclusive interview with the study's first author, Professor Ying Jiang, to provide a deeper understanding of this research.

ACLF Monthly Review" is a special academic review column on ACLF invited by the editorial department of Hepatology Digest, created by the Chinese Acute-on-Chronic Liver Failure Consortium (Ch-CLIF-C). Each month, this column focuses on a specific area related to ACLF, aiming to popularize the concept and significance of ACLF and help readers quickly understand developments in the field. This column is intended to benefit both liver disease experts and researchers who need to understand current hotspots in the field, as well as frontline clinical practitioners who require practical knowledge.

Epstein-Barr virus (EBV) infection is widespread among adults, yet there is no standard treatment for EBV-positive hematologic malignancies, leading to poor patient outcomes. At the 29th Annual Meeting of the European Hematology Association (EHA), Professor Chunrui Li from Tongji Hospital of Huazhong University of Science and Technology presented the results of her team’s Phase I exploratory trial of the KSD-101 dendritic cell vaccine in treating EBV-related hematologic malignancies. This study brings new hope for treating these diseases. Oncology Frontier-Hematology Frontier interviewed Professor Li to delve into this innovative research and discuss the potential impact of KSD-101 on the future of hematologic malignancy treatment.

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). At the 29th European Hematology Association (EHA) Annual Meeting held in Madrid, Spain, from June 13 to 16, 2024, notable advancements were made in MPN research. Oncology Frontier-Hematology Frontier invited Professor Minghui Duan from the Department of Hematology, Peking Union Medical College Hospital, to introduce and provide an in-depth review of two significant studies on myelofibrosis treatment. We hope Professor Duan's insights will help us understand the research progress in this field and provide important references for future research and treatment.

To help clinical hepatologists broaden their horizons and enrich their practical experience, the Hepatology Digest journal has invited Professor Shanhong Tang's team from the Department of Gastroenterology at General Hospital of Western Theater Command to create the "Liver Challenging Cases" column. This column compiles classic cases encountered by Professor Tang’s team over years of clinical practice and will periodically include complex or rare cases from renowned academic journals. The focus is on elucidating diagnostic and therapeutic approaches for various liver diseases, providing valuable clinical insights for colleagues.

In this enlightening interview, Professor Xiaofan Zhu discusses cutting-edge methods for MRD detection and risk stratification in pediatric AML, highlighting the promising role of ctDNA testing.

✨ Ordinary Yet Extraordinary: The Diverse Roles of Doctors in the Fight Against Disease 🌟 - An Interview with Professor Sheng Yan

Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients' vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several rapid oral reports focused on the challenges of UM treatment and presented the latest research findings. Oncology Frontier has compiled relevant studies for readers.

In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.